Actinium Pharmaceuticals Inc (ATNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $51.56M
Last updated: Nov 17, 2026 at 11:04 AM ET
Actinium Pharmaceuticals Inc (ATNM) Stock Forecast
Analysts expect Actinium Pharmaceuticals (ATNM) to earn $0.14 per share in the fiscal year ending Dec 31, 2026, on revenue of $35.00M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.53.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 2 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss.
- Fiscal year ending Dec 31, 2026
- $0.14
- EPS consensus, revenue $35.00M
- Fiscal year ending Dec 31, 2027
- -$0.53
- EPS consensus
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.14 | $0.12 to $0.16 | 2 | $35.00M | $35.00M to $35.00M | 3 |
| Dec 31, 2027 | -$0.53 | -$0.72 to -$0.33 | 2 | N/A | N/A | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.31 to -$0.15 | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a loss of $0.91 to a profit.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.14 | $0.14 | $0.14 | $0.14 | -$0.91 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.53 | -$0.53 | -$0.53 | -$0.53 | -$0.35 | N/A |
Frequently Asked Questions About ATNM
What is the ATNM stock forecast?
Consensus analyst estimates put Actinium Pharmaceuticals's EPS at $0.14 for the fiscal year ending Dec 31, 2026, on revenue of $35.00M. The consensus rating from 3 analysts is Buy.
How do analysts rate ATNM stock?
Of 3 analysts covering Actinium Pharmaceuticals, 1 rates it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ATNM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.14, with estimates from $0.12 to $0.16 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.53, with estimates from -$0.72 to -$0.33 from 2 analysts.
What revenue do analysts expect from Actinium Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $35.00M, with estimates from $35.00M to $35.00M.
How many analysts cover ATNM?
3 analysts rate Actinium Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ATNM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors